Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer

Go back to Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
(NASDAQ: TYME) Delayed: 0.98 +0.01 (1.03%)
Previous Close $0.97    52 Week High
Open $0.97    52 Week Low
Day High $0.99    P/E N/A 
Day Low $0.97    EPS
Volume 847,756